Abstract:The global prevalence of RNA virus infections has presented significant challenges to public health in recent years, necessitating the expansion of its alternative therapeutic library. Due to its evolutional conservation, RNA-dependent RNA polymerase (RdRp) has emerged as a potential target for broad-spectrum antiviral nucleoside analogues. However, after over half a century of structural modification, exploring unclaimed chemical space using frequently-used structural substitution methods to design new nucleoside analogues is challenging. In this study, we explore the use of the "ring-opening" strategy to design new base mimics, thereby using these base mimics to design new nucleoside analogues with broad-spectrum antiviral activities. A total of 29 compounds were synthesized. Their activity against viral RdRp was initially screened using an influenza A virus RdRp high-throughput screening model. Then, the antiviral activity of 38a was verified against influenza virus strain A/PR/8/34 (H1N1), demonstrating a 50% inhibitory concentration (IC50) value of 9.95 μM, which was superior to that of ribavirin (the positive control, IC50 = 11.43 μM). Moreover, 38a also has inhibitory activity against coronavirus 229E with an IC50 of 30.82 μM. In addition, compounds 42 and 46f exhibit an 82% inhibition rate against vesicular stomatitis virus at a concentration of 20 μM and hardly induce cytotoxicity in host cells. This work demonstrates the feasibility of designing nucleoside analogues with "ring-opening" bases and suggests the "ring-opening" nucleosides may have greater polarity, and designing prodrugs is an important aspect of optimizing their antiviral activity. Future research should focus on enhancing the conformational restriction of open-loop bases to mimic Watson-Crick base pairing better and improve antiviral activity.

Expanding the activity spectrum of antiviral agents

Paving new roads toward the advancement of broad‐spectrum antiviral agents

The SAR-based Development of Small Molecular HBV Capsid Assembly Modulators

Antiviral Natural Products Against Chronic Hepatitis B: Recent Developments

The urgent need for pan-antiviral agents: from multitarget discovery to multiscale design

A Broad Antiviral Strategy: Inhibitors of Human DHODH Pave the Way for Host-Targeting Antivirals against Emerging and Re-Emerging Viruses

Discovery, Optimization and Target Identification of Novel Potent Broad-Spectrum Antiviral Inhibitors.

Novel Broad-Spectrum Antiviral Inhibitors Targeting Host Factors Essential for Replication of Pathogenic RNA Viruses

Preclinical Antiviral and Safety Profiling of the HBV RNA Destabilizer AB-161

Discovery of Broad-Spectrum Herpes Antiviral Oxazolidinone Amide Derivatives and Their Structure-Activity Relationships

Broad‐Spectrum Antiviral Peptides and Polymers

Design of novel broad-spectrum antiviral nucleoside analogues using natural bases ring-opening strategy

Emerging Antivirals for the Treatment of Hepatitis B

Recent advance of the hepatitis B virus inhibitors: a medicinal chemistry overview

Therapeutic potential of boswellic acids: an update patent review (2016-2023)

The urgency to expand the antiviral indications of general chronic hepatitis B patients

Emerging antiviral therapeutics for human adenovirus infection: Recent developments and novel strategies

Development of broad-spectrum enterovirus antivirals based on quinoline scaffold

Antivirals against human polyomaviruses: Leaving no stone unturned

Phenoxazine nucleoside derivatives with a multiple activity against RNA and DNA viruses

Medicinal chemistry strategies toward broad-spectrum antiviral agents to prevent next pandemics